MedTrace Logo

Study of TAVO101 in Healthy Volunteers

NCT05298046 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-11-19

No results posted yet for this study

Summary

This is a Phase 1, single ascending dose study designed to investigate TAVO101, administered as an IV infusion in healthy subjects. This study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAVO101.

Conditions

  • Healthy Subjects

Interventions

DRUG

Experimental: TAVO101

TAVO101 single ascending dose IV infusion.

OTHER

Other: Placebo

Placebo single ascending dose IV infusion.

Sponsors & Collaborators

  • Tavotek Biotherapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-11
Primary Completion
2024-06-01
Completion
2024-09-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05298046 on ClinicalTrials.gov